持续推荐创新 药械及产业链。创新药高景气，持续推荐价值有望迎来重估的Pharma，维持恒瑞医药、翰森制药、三生制药、华东医药、恩华药业增持评级，相关标的：石药集团；持续推荐创新管线逐步兑现、业绩进入放量期的Biopharma/Biotech，维持科伦博泰生物、信达生物、新诺威、百利天恒、映恩生物、京新药业、特宝生物、我武生物增持评级；推荐受益创新，景气度修复的CXO 及制药上游，维持皓元医药、...
Source Link持续推荐创新 药械及产业链。创新药高景气，持续推荐价值有望迎来重估的Pharma，维持恒瑞医药、翰森制药、三生制药、华东医药、恩华药业增持评级，相关标的：石药集团；持续推荐创新管线逐步兑现、业绩进入放量期的Biopharma/Biotech，维持科伦博泰生物、信达生物、新诺威、百利天恒、映恩生物、京新药业、特宝生物、我武生物增持评级；推荐受益创新，景气度修复的CXO 及制药上游，维持皓元医药、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.